Aprobemos el uso de #Olaparib para el #cáncer de #mama con mutaciones genéticas BRCA 1 y BRCA 2 en etapa temprana - ¡Firma la petición! https://c.org/LpqTXpHXPT a través de @change_es #SanidadPública
Firma la petición

Aprobemos el uso de Olaparib para el cáncer de mama con mutaciones genéticas BRCA 1 y BRCA 2 en etapa temprana

Change.org
💊💉 #olaparib SmPC for Lynparza 100 mg film-coated tablets has been updated with changes to sections 4.1 Therapeutic indications; 4.2 Posology; 4.4 Special warnings; 4.5 Interaction with other medicinal products; 4.6 Fertility, pregnancy; 4.8 Undesirable effects; 5.1 Pharmacodynamic; 5.2 Pharmacokinetic; Revised: 09/12/2024. 🌐 https://www.medicines.org.uk/emc/product/9204/smpc Change log: https://www.medicines.org.uk/emc/product/9204/smpc/history
Lynparza 100mg Film-Coated Tablets - Summary of Product Characteristics (SmPC) - (emc)

Lynparza 100mg Film-Coated Tablets - Summary of Product Characteristics (SmPC) by AstraZeneca UK Limited

💊💉 #olaparib
SmPC for Lynparza 150 mg film-coated tablets has been updated with changes to sections 4.2 Posology and method of administration; 4.4 Special warnings and precautions for use; 5.1 Pharmacodynamic properties; 10. Date of revision of the text on 23/01/2024.
🌐 https://www.medicines.org.uk/emc/product/9488/smpc
Change log: https://www.medicines.org.uk/emc/product/9488/smpc/history
Lynparza 150mg Film-Coated Tablets - Summary of Product Characteristics (SmPC) - (emc)

Lynparza 150mg Film-Coated Tablets - Summary of Product Characteristics (SmPC) by AstraZeneca UK Limited

💊💉 #olaparib
SmPC for Lynparza 100 mg film-coated tablets has been updated with changes to sections 4.2 Posology and method of administration; 5.1 Pharmacodynamic properties; 10. Date of revision of the text on 23/01/2024.
🌐 https://www.medicines.org.uk/emc/product/9204/smpc
Change log: https://www.medicines.org.uk/emc/product/9204/smpc/history
Lynparza 100mg Film-Coated Tablets - Summary of Product Characteristics (SmPC) - (emc)

Lynparza 100mg Film-Coated Tablets - Summary of Product Characteristics (SmPC) by AstraZeneca UK Limited

💊💉 #olaparib
SmPC for Lynparza 150 mg film-coated tablets has been updated with changes to sections 4.2 Posology and method of administration; 4.4 Special warnings and precautions for use; 4.8 Undesirable effects; 5.1 Pharmacodynamic properties; 10. Date of revision of the text on 19/12/2023.
🌐 https://www.medicines.org.uk/emc/product/9488/smpc
Change log: https://www.medicines.org.uk/emc/product/9488/smpc/history
Lynparza 150mg Film-Coated Tablets - Summary of Product Characteristics (SmPC) - (emc)

Lynparza 150mg Film-Coated Tablets - Summary of Product Characteristics (SmPC) by AstraZeneca UK Limited

💊💉 #olaparib
SmPC for Lynparza 100 mg film-coated tablets has been updated with changes to sections 4.2 Posology and method of administration; 4.8 Undesirable effects; 5.1 Pharmacodynamic properties; 10. Date of revision of the text on 19/12/2023.
🌐 https://www.medicines.org.uk/emc/product/9204/smpc
Change log: https://www.medicines.org.uk/emc/product/9204/smpc/history
Lynparza 100mg Film-Coated Tablets - Summary of Product Characteristics (SmPC) - (emc)

Lynparza 100mg Film-Coated Tablets - Summary of Product Characteristics (SmPC) by AstraZeneca UK Limited

"In conclusion, the newly identified PARP1-CTF18-Polϵ #exonuclease axis and HDR act independently to prevent fork collapse at single-ended double-strand breaks. #Olaparib inhibits this axis, explaining the pronounced #cytotoxic effects of olaparib on HDR-deficient cells."

https://academic.oup.com/nar/advance-article/doi/10.1093/nar/gkad999/7369941

#polymerase #DNA #replication #mutations #cancer #oncology #cellBiology #genetics

The proofreading exonuclease of leading-strand DNA polymerase epsilon prevents replication fork collapse at broken template strands

Abstract. Leading-strand DNA replication by polymerase epsilon (Polϵ) across single-strand breaks (SSBs) causes single-ended double-strand breaks (seDSBs), whic

OUP Academic
💊💉 #olaparib
SmPC for Lynparza 150 mg film-coated tablets has been updated with changes to sections 4.4 Special warnings and precautions for use; 4.8 Undesirable effects; 10. Date of revision of the text on 20/10/2023.
🌐 https://www.medicines.org.uk/emc/product/9488/smpc
Change log: https://www.medicines.org.uk/emc/product/9488/smpc/history
Lynparza 150mg Film-Coated Tablets - Summary of Product Characteristics (SmPC) - (emc)

Lynparza 150mg Film-Coated Tablets - Summary of Product Characteristics (SmPC) by AstraZeneca UK Limited

💊💉 #olaparib
SmPC for Lynparza 100 mg film-coated tablets has been updated with changes to sections 4.4 Special warnings and precautions for use; 4.8 Undesirable effects; 10. Date of revision of the text on 20/10/2023.
🌐 https://www.medicines.org.uk/emc/product/9204/smpc
Change log: https://www.medicines.org.uk/emc/product/9204/smpc/history
Lynparza 100mg Film-Coated Tablets - Summary of Product Characteristics (SmPC) - (emc)

Lynparza 100mg Film-Coated Tablets - Summary of Product Characteristics (SmPC) by AstraZeneca UK Limited

@EmboMolMed My mom received #Olaparib in a clinical trial (PAOLA-1). It saved her life. Now, we are collecting donations to get Olaparib as a long-time treatment. If you want to help, please do so, thanks: https://www.gofundme.com/f/olaparib-als-erhaltungstherapie-gegen-krebs?utm_campaign=m_pd+share-sheet&utm_content=undefined&utm_location=undefined&utm_medium=copy_link_all&utm_source=customer&utm_term=undefined